PREVENAR™’s Extended Indication to Include Pneumonia and Otitis Media, Received Positive Opinion from EU Committee
PREVENAR is currently approved for active immunization of children from 2 months to 5 years of age against sepsis, meningitis, bacteraemic pneumonia and bacteraemia caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.
PREVENAR™ is the first and only conjugate vaccine that demonstrated efficacy in the reduction of the incidence of pneumococcal disease (PD) in infants and toddlers.
The CHMP recommendations of PREVENAR will now be forwarded to the European Commission (EC) for final approval – expected in the second quarter of 2007. Wyeth Pharmaceuticals (10944776) is a division of Wyeth (NYSE: WYE).
Find more details from the press release.
Comment Preview